• Tonix Pharmaceuticals published a medical research presentation outlining TNX-4800, a long-acting, bactericidal human anti-OspA monoclonal antibody being developed to prevent Lyme disease in the U.S.
• Program concept centers on passive immunity designed to block Borrelia transmission in the tick midgut; a two-dose subcutaneous regimen on day 1 and day 56 is expected to provide at least 6 months of protection.
• Preclinical nonhuman primate challenge data cited protection rates of 83% to 100% across 3 mg/kg to 90 mg/kg dosing cohorts, versus 0% in an irrelevant IgG control group.
• Phase 1 results in 44 healthy volunteers described TNX-4800 as safe and well tolerated; 1 serious adverse event occurred in the placebo group, with mostly mild treatment-emergent adverse events in treated participants.
• Tonix also highlighted $185.5 million in cash as of March 31, 2026, with no debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.